Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity

Lancet Oncology

Volumn 6, Issue 2, 2005, Pages 67-

  Jones, Robin L ^a,b,c   Miles, David W ^a,b,c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; TRASTUZUMAB;

CARDIOTOXICITY; DOSE RESPONSE; ECHOCARDIOGRAPHY; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HUMAN; KAPOSI SARCOMA; NOTE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 13344280265     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)01719-5     Document Type: Letter

References (6)

1. Young AM Dhillon T Bower M. Cardiotoxicity after liposomal anthracyclines Lancet Oncol 5 2004 654
2. Jones RL Berry GJ Rubens RD Miles DW. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin Lancet Oncol 5 2004 575-577
3. 2 Ann Oncol 11 2000 1029-1033
4. Gabizon AA, Lyass O. Cardiac safety of pegylated liposomal doxorubicin (PLD) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003; 22: 763 (abstr)
5. Mustafa M. Decreased risk of cardiotoxicity with long-term use of Doxil/Caelyx at high lifetime cumulative doses in patients with AIDS-related Kaposi's sarcoma (KS). Proc Am Soc Clin Oncol 2001; 20: Abstr 2915
6. Meinardi MT van der Graaf WTA van Veldhuisen DJ et al. Detection of anthracycline-induced cardiotoxicity Cancer Treat Rev 25 1999 237-247